Pipeline Progress at Synergy Pharma - Analyst Blog
December 31 2012 - 8:02AM
Zacks
Synergy Pharmaceuticals (SGYP) recently
initiated a phase IIb study with plecanatide for the treatment of
patients suffering from constipation-predominant irritable bowel
syndrome (IBS-C).
Synergy Pharma will be enrolling 350 patients suffering from
IBS-C around 70 sites in the US. These patients will be treated
with any one of the four doses of plecanatide (0.3, 1.0, 3.0, or
9.0 mg) or placebo for 12 weeks.
The trial will be evaluating the average change in complete
spontaneous bowel movements (CSBM's) during the trial period in
comparison to their baseline weekly CSBM rate that was established
during the screening phase of the study. In addition to this,
Synergy Pharma will be evaluating spontaneous bowel movements
(SBM's) and daily abdominal pain, discomfort along with bloating
scores and impact of the candidate on disease-specific quality of
life measures during the study.
The IBS-C market already has players like Takeda
Pharmaceutical Company Limited (TKPYY),
ForestLaboratories Inc. (FRX) and
Ironwood Pharmaceuticals (IRWD).
We note that Synergy Pharma is conducting an independent study
on plecanatide for the treatment of patients suffering from chronic
idiopathic constipation. The company expects to complete the study
soon and report top-line results within a few weeks.
Apart from plecanatide, Synergy Pharma also completed a phase I
clinical trial on SP-333, a guanylate cyclase C (GC-C) agonist,
being developed for the treatment of ulcerative colitis (UC) and
other GI diseases. The company now expects to initiate a
multi-dose, dose-escalation trial in patients by January 2013.
Synergy Pharma currently carries a Zacks #3 Rank (Hold) in the
short run. Meanwhile, Ironwood Pharma carries a Zacks #2 Rank
(Buy).
FOREST LABS A (FRX): Free Stock Analysis Report
IRONWOOD PHARMA (IRWD): Free Stock Analysis Report
SYNERGY PHARMAC (SGYP): Free Stock Analysis Report
(TKPYY): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024